Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Narlaprevir - R-Pharm

Drug Profile

Narlaprevir - R-Pharm

Alternative Names: Arlansa; SCH-900518

Latest Information Update: 30 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co; R-Pharm; Schering-Plough; Texas Liver Institute
  • Class Antivirals; Dipeptides; Sulfones
  • Mechanism of Action Hepatitis C protease inhibitors; Hepatitis C virus NS3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered Hepatitis C

Most Recent Events

  • 11 Apr 2018 Discontinued - Clinical-Phase-Unknown for Hepatitis C in Europe (PO)
  • 11 Apr 2018 Registered for Hepatitis C (Combination therapy) in Russia (PO) (R-pharm pipeline, April 2018)
  • 27 Nov 2017 R-Pharm in collaboration with Almedis initiates enrolment in a phase II trial for Hepatitis C in Russia (NCT03485846)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top